Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
June 15 CC for Q4 Earnings at 11AM
per fidelity
(ONTY) Oncothyreon Inc. changes its name
http://www.streetinsider.com/Corporate+News/Oncothyreon+(ONTY)+Changes+Name+to+Cascadian+Therapeutics%3B+Will+Begin+Trading+Under+Ticker+CASC/11720500.html
Oncothyreon (ONTY) Changes Name to Cascadian Therapeutics; Will Begin Trading Under Ticker 'CASC'
Oncothyreon Inc. (Nasdaq: ONTY) (Nasdaq: CASC) announced that the Company is changing its name to Cascadian Therapeutics, Inc. and will trade on the NASDAQ Global Select Market under the new ticker symbol “CASC,” effective at market open on June 9, 2016.
The new name reflects the change in the Company’s focus from therapeutic vaccines to advancing targeted treatments for cancer. The Company’s lead product candidate, ONT-380, is an orally bioavailable, highly selective small molecule HER2 inhibitor being developed as a combination therapy to treat HER2+ advanced or metastatic breast cancer.
“We chose to implement a new name to emphasize our organization’s transformation and vision for the future,” said Scott Myers, President and CEO of Cascadian Therapeutics. “By incorporating the imagery of the Cascade Mountains, our goal was to highlight our Company’s heritage, but more importantly, to underscore our transition away from therapeutic vaccines to developing innovative targeted therapies for cancers, with a lead indication for metastatic HER2+ breast cancer. HER2CLIMB, our Phase 2 randomized, double-blind, placebo-controlled trial, was also named in the spirit of our mission to improve outcomes in this disease. We look forward to providing an update on this important program at our upcoming R&D Day.”
On June 14th at 2 p.m. Eastern, the Company will present updated data from the ongoing “Triplet” Phase 1b trial, in addition to the future product development plans for ONT-380, at the Company’s R&D Day in New York City. The webcast will be available on the Events and Presentations Page of the Company’s website at www.cascadianrx.com.
No action is required by stockholders with respect to the name change. The Company's common stock has been assigned a new CUSIP number of 14740B 101 in connection with the name change. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.
Positive Phase 1 results
http://finance.yahoo.com/news/oncothyreon-presents-phase-1b-results-130000548.html
Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 in HER2+ Metastatic Breast Cancer at ASCO
Encouraging results in ONT-380 combination therapy in patients with and without brain metastases
CHICAGO, June 05, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (ONTY), a clinical-stage biopharmaceutical company, today announced the presentation of clinical data on its lead product candidate, ONT-380, at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO). ONT-380 is a highly selective small molecule HER2 inhibitor being developed in combination to treat HER2+ advanced or metastatic breast cancer.
Data from a poster presentation (#513 “Efficacy Results of a Phase 1b Study of ONT-380, a CNS-Penetrant TKI, in Combination with T-DM1 in HER2+ Metastatic Breast Cancer (MBC), Including Patients with Brain Metastases”) showed promising safety and efficacy results in a Phase 1b study as treatment in patients with progressive disease who were previously treated with trastuzumab and a taxane.
“These results continue to demonstrate the potential of ONT-380 in the treatment of HER2+ breast cancer,” said Luke Walker, M.D., Vice President, Clinical Development. “The early evidence of systemic activity, combined with a favorable safety profile and encouraging activity against brain metastases, is supportive of further development of this combination.”
“Our internal team and advisors believe that these data are very intriguing and that the T-DM1 combination warrants further exploration,” commented Scott Myers, President and CEO. “However, given current resources and the development requirements in this setting, we will pursue this combination in cooperation with others or develop ourselves at a later date. Going forward, we remain focused on advancing our ongoing Phase 2 ‘Triplet’ trial with ONT-380 in combination with capecitabine and trastuzumab.”
Updated data from the ongoing “Triplet” Phase 1b trial and the future ONT-380 product development plan will be presented at the Company’s R&D Day on June 14th in New York City.
Shareholder meeting June 23
Q2 Earnings Aug 4 after market closes (unconfirmed)
according to Fidelity
For what its worth....Fidelity IS reporting June 14 "ELTP to announce Q4 earnings After Market" but also says "unconfirmed"
Nothing else applied to that statement. Just a quick snip it.
ELTP on Sheff's watchlist. Stated that the company is expecting an ADCOM and possible PDUFA delay.
Can anyone else confirm that info?
LPCN making a come back today. Up 13%!
News isn't expected until January. Anything that comes before that should be considered early (which would be awesome!)
Unfortunately I won't be getting rich on this one but hopefully getting a nice bonus;)
I bought in last year and earlier this year, but still avg low .40's with a small chunk of 10k shares
ELTP - Thanks for the shout out. I had work all day today (Army stuff) so I didn't get to watch my stocks. Guess I'll hold onto ELTP a little longer than I thought.
Thanks for the tip Smurf. I typically go for the smaller percentages as suggested but I think I'm getting caught up with ELTP because it went up so quick. But you're right. I locked all my money in ELTP and IGXT not leaving any funds to go play others. Can't complain at an 82% profit this month!
Nope. Just bios. I find them easier to predict fluctuations in the stock prices using studies results, FDA decision dates, etc. Similar to the fashion of how Sheff does things....which is how I found Smurfs board.
20 with just about a $60,000 stock. That's awesome man. I started at an earlier age like you (I'm 29) but made A LOT of mistakes. You seem to be doing great. Keep it up.
IGXT - this one I've been holding for awhile. I think my average is in the .50's. But again only have around 5500 shares. I did have 8500 but I sold 3000 when it hit above a $1. Took that money and invest in ELTP. I'm a small time investor with the hopes of growing it to be something more substantial (obviously...lol).
Wow awesome man. Congrats. Wish I could say that for myself.
I hold such a small position (5600 @ .515). Not sure if I'd rather hold it long or sell half to at least get my money back. If I sold half, my core wouldn't be worth very much but profits are profits I suppose.
ELTP - Looking good today with the news that came out. Wish I would have gotten in when you all have but cant complain at .515. Still making about 82% on it. You going long on this one Smurf?
ELTP - I can roll with that. What's the minimum for uplisting ...$4 haha
ELTP - smurf, how long do you think you're going to hold ELTP?
I had a small buy for 7500 @ .405 last Friday but never got filled. I think around the time I put my order in it only dipped to .406. Bummer.
Looking for an entry point. Any advice or did I miss the boat?
Estimates of PPS if/when IGXT gets approval?
Or would this just be a guessing game?
Dean has proven to be a man of his word plenty of times. With my personal experiences with him I wouldn't think otherwise. IMO we're in good shape here.
Probably has no value to anyone but myself but I'm currently deployed in Afghanistan and Dean Janes sent 2 huge care packages to me and our soldiers just like he said he would.
I told him, (awhile back) on facebook, I look forward to see where IMGG is at after I get back from deployment and he asked for my APO. He kept his word.
That's all that matters to me. In for the long haul.
I'm actually up closer to 600% and continue to buy in at the dips. Don't be upset you couldn't get in at rock bottom prices like the rest of us longs.
We've done the research and we've been around long enough to know better to listen to bashers like you.
Leave your posts for the yahoo boards my friend.
Can someone forward the email to me from Recon.....I just home from work and saw he had an email to share with everyone.
Manalo84@aol.com
TIA
Current MoneyTV
I'm friends with Dean on his facebook where he posted his short MoneyTV link. It's literally a minute long.
http://www.facebook.com/home.php?ref=home#/video/video.php?v=1227794547139&ref=mf
looks like it. Guess we'll find out.
Still looking for the .02 you predicted this week....
lmao!
Posted by: oilin07
In reply to: None
Date:4/24/2008 2:24:06 PM
Post #of 2769
Next week back to atleast .02. em
Observant one as well.
Did you figure that all by yourself moron?
Folks we have a winner here.
Give me a break Moron. Look at the pps. Look at the chart. What more hard evidence do you need. You base you info off of PR's full of lies and a company that is paid by UPDA to give such a high prediction(beacon). You're a fool to think and hope this stock is going to take off.
Yes YOU are a spammer. Everyone knows your a spammer. And soon you posts will be deleted because you're a spammer.
Moron
without reason or facts is does count as spam.
Moron
Why though?
Statements without facts hold no ground. Its considered spam.
Give it up man...your statements are nothing here. Moron
To say we're at .02's next week is ridiculous statement.
- Where are your facts, proof?
- Why do you think this?
Please share your so called knowledge.
Again, this guy is paid by the company. A spammer.
oil/gas properties/production doesn't matter if the company isn't making any money. Look at what's in front of you.
I agree natural gas is in demand. No duh. The company however is pocketing all the cash under the table. This company is crap.
People this guy is a pumper, paid by the company. This a good stock to LOSE ALL your money.
Always next week or next month with you. Have you EVER been right? No. Why would you be now?
Moron
This stock is a scam. Don't buy.
Look at the charts.
I care because I took the plunge awhile back but sold once it got below .02. Now I people like your are encourage people to buy by building false hopes. This company hasn't done anything to help their shareholders so why would anything change?
You're not doing anything but encouraging people to lose their money.
Can you honestly say this is a good stock to invest in?
Answer that.
If you say yes then we know who you are.
Haha...good news coming?
This moron is paid for sure. Look at the pps right now compared to his posts. Complete bs. Yes I went there.
If you're not paid by the company then you have to be missing a few nuts and bolts upstairs because you're down some big dollars my friend.
This company is going bankrupt and you're going with them.